Provided by Tiger Trade Technology Pte. Ltd.

Ocuphire Pharma, Inc.

1.17
0.0000
Volume:- -
Turnover:792.87K
Market Cap:30.65M
PE:-1.97
High:1.17
Open:1.17
Low:1.17
Close:1.17
52wk High:3.40
52wk Low:1.15
Shares:26.20M
Float Shares:24.52M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5951
EPS(LYR):-0.4625
ROE:-36.01%
ROA:-21.35%
PB:0.75
PE(LYR):-2.53

Loading ...

Company Profile

Company Name:
Ocuphire Pharma, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.